• Moderate-severe menopausal vasomotor symptoms:
    • PO 1-2mg OD *3/52 then 1/52 off
    • Add progestin *10-14 days/4week cycle if intact uterus
  • Menopausal vulvovaginal atrophy:
    • PO 1-2mg OD *3/52 then 1/52 off
    • Add progestin *10-14 days/4week cycle if intact uterus
  • Prevention of osteoporosis:
    • 5mg PO OD *3/52 then 1/52 off
  • Metastatic breast cancer:
    • 10mg TDS *3/12 
  • Prostate cancer:
    • PO 1-2mg TDS * ≥3 months
  • Hypoestrogenism from castration, hypogonadism or ovarian failure:
    • PO 1-2mg OD *3/52 then 1/52 off
    • Add progestin *10-14 days/4week cycle if intact uterus
  • Palliative care in metastatic cancer:
    • PO 10mg TDS *≥3 months 
  • Palliative care in advanced prostrate cancer:
    • PO 1-2mg TDS
  • Tablet:
    • 1mg
    • 2mg

None remarkable

Endogenous estrogen

It reduces release of gonadotropin-releasing hormone and LHRH from the hypothalamus. It acts on the estrogen receptors to relieve vasomotor systems (such as hot flashes) and urogenital symptoms (such as vaginal dryness and dyspareunia)

  • Vaginal bleeding/spotting
  • Breast changes
  • Breast pain
  • Musculoskeletal pain
  • Abdominal cramps
  • Abdominal distension
  • Dyspepsia
  • Influenza-like symptoms
  • Nausea & vomiting
  • Constipation
  • Cervical secretion changes
  • Migraine
  • Fluid retention
  • Elevated BP
  • Insomnia
  • Mood changes
  • Vulvovaginal candidiasis
  • Glucose intolerance
  • Weight changes
  • Libido changes
  • Contact lens intolerance
  • Hypersensitivity to class/components
  • Undiagnosed vaginal bleeding
  • Breast cancer or history
  • Estrogen-dependent cancer or history
  • Venous thromboembolism or history
  • Arterial thromboembolism within 12 months
  • Protein C & S deficiency
  • Thrombophilic disorder
  • Hepatic disease
  • Hepatic impairment

WARNING:

  • Increased risk of endometrial cancer
  • Increased risk of stroke, MI, stroke, PE/DVT and invasive breast CA in postmenopausal women
  • Increased risk of invasive breast cancer
  • Ospemifene

                          Drug Status

Availability Prescription only
Pregnancy Not indicated
Breastfeeding Not indicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Coming soon Coming soon Coming soon Coming soon Coming soon Coming soon